Consensus on the diagnosis and treatment of PROS (PIK3CA-related overgrowth spectrum). Russian version
Authors:
- G. B. SagoyanGSG. B. Sagoyan
- N. V. ZhukovNZN. V. Zhukov
- В. В. СтрельниковВСВ. В. Стрельников
- R. A. KhagurovRKR. A. Khagurov
- A. M. SuleymanovaASA. M. Suleymanova
- Yu. M. MareevaYMYu. M. Mareeva
- R. V. GarbuzovRGR. V. Garbuzov
- E. N. ImyanitovEIE. N. Imyanitov
- Yu. V. DinikinaYDYu. V. Dinikina
- S. I. KutsevSKS. I. Kutsev
- E. K. DonyushEDE. K. Donyush
- K. I. KirgizovKKK. I. Kirgizov
Open Access
- 19 July 2023
- journal article
- research article
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 117-130
Abstract
PROS (PIK3CA-Related Overgrowth Spectrum) encompasses vascular malformations, lipomatosis and other multiple congenital anomalies resulting from activating somatic mutations in the PIK3CA gene. PROS includes macrodactyly, hemimegalencephaly, muscle hemihypertrophy, facial infiltrating lipomatosis CLOVES, megalencephaly, vascular malformations (capillary, venous, lymphatic, arteriovenous and combined vascular malformations), skin disorders, epidermal nevi, etc.The experts of the Russian Society of Pediatric Oncologists and Hematologists, Russian Association of Pediatric Surgeons and Russian Society of Medical Geneticists developed this consensus statement of diagnostics and treatment of PROS.Keywords
This publication has 11 references indexed in Scilit:
- PIK3CA-related overgrowth: silver bullets from the cancer arsenal?Trends in Molecular Medicine, 2022
- Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrumBritish Journal of Clinical Pharmacology, 2022
- Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisibJournal of Experimental Medicine, 2022
- LBA23 EPIK-P1: Retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programmeAnnals of Oncology, 2021
- A standard of care for individuals with PIK3CA‐related disorders: An international expert consensus statementClinical Genetics, 2021
- A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestationsOrphanet Journal of Rare Diseases, 2021
- Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast CancerDrugs, 2020
- Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrumGenetics in Medicine, 2018
- Cancer-Associated PIK3CA Mutations in Overgrowth DisordersTrends in Molecular Medicine, 2018
- PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluationAmerican Journal of Medical Genetics Part A, 2014